SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending amid a recent announcement of a $2.35 billion senior secured notes offering, leading to community debate around the company's debt strategy and its potential impact on growth. Community members are weighing the implications of this financial move against the backdrop of the AI sector's volatility, discussing whether this is a buying opportunity or a sign of deeper issues. Despite differing opinions, the company's existing contracts and long-term potential in the AI data center space remain central talking points.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending as anticipation builds around the pending CHMP decision on blarcamesine, with community chatter focusing on the potential for approval and its impact on Alzheimer's treatment. Some traders are pointing to short positions and potential manipulation, while longs express confidence in the science and patient benefits, setting the stage for a volatile trading day.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending downwards following its latest earnings report and revised revenue guidance, sparking discussions about management's credibility and future prospects. The community is debating the impact of government shutdowns and contract delays, while also comparing RCAT's performance and management to competitors like ONDS. Despite the short-term concerns, some investors remain optimistic about RCAT's long-term potential in the drone and defense sectors, citing ongoing contracts and expansion into maritime unmanned systems.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as it dips below $100K, sparking debates about whether this is a buying opportunity or the start of a deeper correction. Community members are discussing potential support levels, possible liquidations, and the influence of large holders. Sentiment is mixed, with some seeing a bear trap and others anticipating further downside.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending amid discussions around government contracts and its potential role in lunar infrastructure, particularly with renewed interest after an AFRL contract extension. Community members are weighing the impact of recent acquisitions and revenue potential, as well as speculating on upcoming contract announcements. Some are expressing frustration with the stock's price action despite positive developments.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending due to renewed social media speculation around a past AI server deal and its small float post-reverse split, leading to significant price movement. The community is actively discussing potential breakouts and a possible short squeeze, with some comparing it to previous high-flying stocks. Traders are closely watching key breakout levels, anticipating a potential parabolic run if certain price points are surpassed.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is trending amid discussions about its financial performance and the ongoing release of Epstein-related documents. The community is expressing concerns about the company's future and the potential impact of these external factors, including political opinions and a mix of reactions, from staunch support to harsh criticism. Speculation is also circulating regarding potential market manipulation and the stock's long-term viability.

Cidara Therapeutics, Inc. engages in developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. Its platform, Cloudbreak, enables development of novel drug-Fc conjugates (DFCs) that inhibit specific disease targets while simultaneously engaging the immune system. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Cidara Therapeutics Inc

Cidara Therapeutics is trending amid speculation of a potential acquisition, with community members discussing rumors of a bidding war involving major pharmaceutical companies. The positive Phase 2 clinical data for their influenza candidate CD388 and a recent $339M BARDA award have increased optimism around the stock. Investors are closely watching for further developments, including potential price target updates and signals of a buyout.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Round Rock, TX.

TSS Inc

TSSI is trending due to a significant after-hours drop following disappointing earnings results, with a 40% revenue decrease sparking concern. The community is baffled by the numbers, especially after recent facility upgrades and hiring, with some questioning management and the company's relationship with Dell. Despite a long-term positive outlook, investors are expressing frustration and uncertainty about the immediate future.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending amid Bitcoin's recent volatility and a general market pullback, sparking debates about its correlation to BTC and concerns about debt levels. The community is discussing whether the stock is undervalued, oversold, or headed for a significant correction, with some expressing concerns over management strategy and potential liquidation events, while others anticipate a rebound.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Omeros Corporation Reports Third Quarter 2025 Financial Results

Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2025, which include: Net loss for the third...

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2025, on Thursday, November 13, 2025, after the market closes...

Weekly Stock Market Update: Apple, Taiwan Semiconductor and Novo Nordisk

It was a volatile but ultimately positive week on Wall Street, marked by renewed tensions in the U.S.-China trade war and a strong start to the earnings season. Major banks exceeded expectations...

NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio

Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing survival outcomes in...

Omeros’ stock had&nbsp;its best day on Wednesday ever after H.C. Wainwright raised its price target to $20 from $9 and kept a ‘Buy’ rating, following news of a multibillion-dollar licensing deal with Novo Nordisk for its rare disease drug candidate zaltenibart.<a href="https://stocktwits.com/symbol/OMER">Shares of Omeros</a> jumped 154.1% to close at $10.42 on Wednesday, before slipping 3.1% in after-hours trading, while&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk’s U.S.-listed shares</a> edged up 0.1% to $54.06.The brokerage said Omeros will get $240 million upfront, along with up to $510 million in development and approval milestone payments and as much as $1.3 billion tied to future sales, plus royalties. H.C. Wainwright said the new target reflects the significant non-dilutive cash Omeros will receive and updated risk assumptions for zaltenibart.Under the agreement, Novo Nordisk will take full global control of developing and commercializing zaltenibart, which targets MASP-3, a key protein linked to several rare blood and kidney disorders. The deal could be worth as much as $2.1 billion if all milestones are met. Novo Nordisk said the medicine could become a best-in-class option and will help strengthen its rare disease business.Omeros CEO Gregory Demopulos said teaming up with Novo Nordisk allows the drugmaker to expand zaltenibart’s reach worldwide while Omeros focuses on bringing its own drug, narsoplimab, to market.&nbsp;Novo Nordisk said it plans to start a global phase 3 study of zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH) and explore its use in other rare conditions. The deal is expected to close by late 2025.On Stocktwits, retail sentiment for Omeros was ‘extremely bullish’ amid ‘extremely high’ message volume, while sentiment for Novo Nordisk was ‘extremely bearish’ with ‘low’ message volume.One user on Stocktwits said the royalties from the Novo Nordisk deal alone could be worth billions, adding that despite some short-seller claims, Omeros still has an impressive pipeline and plenty of funding to develop new drugs.&nbsp;<stembedurl>https://stocktwits.com/whatsgood75/message/632507728</stembedurl>Another user said they had done their own research and believe the company is waiting on FDA decisions for other promising treatments, calling Omeros a solid firm with multiple revenue streams and saying they plan to buy more shares.<stembedurl>https://stocktwits.com/SnoddyTradz/message/632496306</stembedurl>While Omeros’ stock has risen 5% so far in 202, Novo Nordisk’s U.S.-listed stock has declined 33% over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Omeros Stock Logs Best Session Ever After HC Wainwright Doubles Target On Novo Nordisk Deal; Retail Sees Big Upside

The rally followed H.C. Wainwright’s price target hike to $20 on the back of a $2.1 billion licensing deal with Novo Nordisk for zaltenibart.

Equity

Danish drugmaker Novo Nordisk (NVO) on Wednesday said that it has entered into a definitive asset purchase and license agreement with Omeros Corporation (OMER) for its drug candidate Zaltenibart.Zaltenibart is in clinical development for rare blood and kidney disorders. Under the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916434">deal,</a> Novo Nordisk will be granted exclusive global rights to develop and commercialize Zaltenibart in all indications.Omeros will receive $340 million in upfront and near-term milestone payments and will be eligible to receive up to a total of $2.1 billion, including commercial milestone payments, in addition to tiered royalties on net sales. Following the closing of the transaction, Novo intends to initiate a global late-stage program for Zaltenibart in paroxysmal nocturnal hemoglobinuria, a rare, acquired blood disorder where the body's immune system mistakenly attacks and destroys red blood cells. Omeros has already reported positive mid-stage data for Zaltenibart in treating the blood disorder.The transaction is expected to close in the fourth quarter of 2025. <a href="https://stocktwits.com/symbol/OMER">OMER shares</a> soared 136% in the pre-market session. On Stocktwits, retail sentiment around OMER jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.“Novo Nordisk is in a strong position to build on the work done by Omeros to maximize the value of this asset and develop Zaltenibart into a differentiated and potentially best-in-class treatment approach for a number of rare blood and kidney disorders,” said Martin Holst Lange, chief scientific officer and executive vice president of Research &amp; Development at Novo Nordisk.Omeros CEO Gregory A. Demopulos said that the company will now focus on securing approval and commercialization of Narsoplimab this quarter for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Novo, meanwhile, will also explore further development of Zaltenibart in a range of other rare blood and kidney disorders.OMER stock rose 7% this year, while NVO shares dropped 34%.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-says-oral-glp-1-drug-reduced-blood-sugar-levels-in-two-late-stage-trials/ch6nxr4R3Nm">Eli Lilly Says Oral GLP-1 Drug Reduced Blood Sugar Levels In Two Late-Stage Trials</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder

Under the deal, Omeros will receive $340 million in upfront and near-term milestone payments and will be eligible to receive up to a total of $2.1 billion, including commercial milestone payments.

Under the deal, Omeros will receive $340 million in upfront and near-term milestone payments and will be eligible to receive up to a total of $2.1 billion, including commercial milestone payments, in addition to tiered royalties on net sales.

Omeros Corporation has filed a marketing authorization application (MAA) with the European Medicines Agency (EMA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).The MAA is based on response-evaluable analyses of patients treated with narsoplimab and a comparison of overall survival with a well-matched external control group.&nbsp;According to the company, the submission shows a 61% response rate and a three-fold improvement in overall survival in the narsoplimab cohort.&nbsp;It also incorporates outcomes from over 130 patients treated under Omeros’ expanded access program.Following the news, H.C. Wainwright reiterated a ‘Buy’ rating and $9 price target on the stock.&nbsp;Analyst Brandon Folkes wrote that the EMA submission supports the view that Omeros “may be entering a phase of rerating” over the next 12 months, driven by potential U.S. approval, EU approval, and renewed appreciation for the broader pipeline.&nbsp;The firm expects narsoplimab to secure regulatory clearance in both regions, creating “significant value” for the company.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.Retail investors voiced concerns after Omeros Corporation’s June 27 shareholder meeting, during which audio reportedly cut out during two critical questions on the company's regulatory outlook.One user claimed that approximately 80 seconds of the meeting, covering responses to questions about the status of the biologics license application (BLA) and the FDA’s ability to meet its PDUFA timeline, were missing from both the live broadcast and its replay.&nbsp;<stembedurl>https://stocktwits.com/WinstonWolfff/message/619393411</stembedurl>“We, as shareholders, deserve to hear the complete responses,” they wrote, adding that Omeros has “a HUGE shareholder relations/communication problem.”Another investor said they emailed Omeros directly, describing the audio loss during the “most important two questions regarding FDA approval” as “beyond embarrassing.”&nbsp;<stembedurl>https://stocktwits.com/TRYII/message/619392905</stembedurl>The user called for a full update and transcript, writing: “Please do the right thing here… Many, many investors are asking and suspicious.”<a href="https://stocktwits.com/symbol/OMER">Omeros'</a> stock has declined 67.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Omeros Seeks EMA Approval For Narsoplimab After Data Shows 3X Survival Boost

The application includes outcomes from more than 130 patients treated under an expanded access program, supporting broader regulatory momentum for narsoplimab. 

Down 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER)

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Omeros Corporation (Nasdaq: OMER) today announced statistical analysis results related to the expanded access program (EAP) for narsoplimab, Omeros first-in-class monoclonal antibody inhibiting the...

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

$IONQ

$RGTI

$QBTS

$QUBT

Are you buying the dip on any of these quantum stocks? 
 
If no, drop a comment.

OMER
Omeros Corporation

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest OMER News

OMEROmeros Corporation